Alexion’s Soliris follow-up Ultomiris snares EU approval

Alexion’s Soliris follow-up Ultomiris snares EU approval

Source: 
Pharmaforum
snippet: 

Alexion has the EU approval it needed for Ultomiris, a follow-up to its rare disease therapy Soliris that will lose patent protection in Europe next year.